Prevalence of medical conditions or comorbidities influencing first-line therapy in unresectable hepatocellular carcinoma in the United States.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-02-01 Epub Date: 2025-01-15 DOI:10.1080/14796694.2024.2444874

Tammy A Schuler, Shital Kamble, Kaushal Desai, Emily Bland, Leonid Dubrovsky, Bruce Feinberg

{"title":"Prevalence of medical conditions or comorbidities influencing first-line therapy in unresectable hepatocellular carcinoma in the United States.","authors":"Tammy A Schuler, Shital Kamble, Kaushal Desai, Emily Bland, Leonid Dubrovsky, Bruce Feinberg","doi":"10.1080/14796694.2024.2444874","DOIUrl":null,"url":null,"abstract":"Introduction: Given treatment landscape changes, understanding the prevalence of medical conditions/comorbidities influencing real-world unresectable hepatocellular carcinoma (uHCC) treatment decisions is key for improving outcomes.Patients and methods: In a retrospective chart review, physicians abstracted data from uHCC patients initiating first-line treatment (1L) between June 2020 and April 2022. Frequencies of medical conditions/comorbidities at 1L initiation were reported.Results: Among 433 patients, 77% had Barcelona Cancer Liver Clinic (BCLC)-C and 37% had Child-Pugh B status. Overall, 51% had ≥ 1 condition/comorbidity making them potentially less suitable for a 1L immunotherapy combination regimen (e.g. atezolizumab plus bevacizumab), including upper/lower gastrointestinal bleeding risk (38%), chronic kidney disease (15%), history of thromboembolic events (12%), and autoimmune disorders (5%).Discussion: More than half of the patients had ≥ 1 medical condition/comorbidity making them potentially less suitable for a 1L immunotherapy combination. This study provides timely insight into how immunotherapy combinations are being used in the real-world setting among a large number of patients.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"313-319"},"PeriodicalIF":3.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792838/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2444874","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Given treatment landscape changes, understanding the prevalence of medical conditions/comorbidities influencing real-world unresectable hepatocellular carcinoma (uHCC) treatment decisions is key for improving outcomes.

Patients and methods: In a retrospective chart review, physicians abstracted data from uHCC patients initiating first-line treatment (1L) between June 2020 and April 2022. Frequencies of medical conditions/comorbidities at 1L initiation were reported.

Results: Among 433 patients, 77% had Barcelona Cancer Liver Clinic (BCLC)-C and 37% had Child-Pugh B status. Overall, 51% had ≥ 1 condition/comorbidity making them potentially less suitable for a 1L immunotherapy combination regimen (e.g. atezolizumab plus bevacizumab), including upper/lower gastrointestinal bleeding risk (38%), chronic kidney disease (15%), history of thromboembolic events (12%), and autoimmune disorders (5%).

Discussion: More than half of the patients had ≥ 1 medical condition/comorbidity making them potentially less suitable for a 1L immunotherapy combination. This study provides timely insight into how immunotherapy combinations are being used in the real-world setting among a large number of patients.

查看原文本刊更多论文

在美国，影响不可切除肝细胞癌一线治疗的医疗条件或合并症的患病率

导读：鉴于治疗环境的变化，了解影响现实世界不可切除肝细胞癌（uHCC）治疗决策的医疗条件/合并症的患病率是改善预后的关键。患者和方法：在一项回顾性图表回顾中，医生提取了2020年6月至2022年4月期间开始一线治疗的uHCC患者的数据。报告了1L开始时的医疗条件/合并症的频率。结果：在433例患者中，77%为巴塞罗那肝癌临床(BCLC)-C， 37%为Child-Pugh B状态。总体而言，51%的患者有≥1种疾病/合并症，这使得他们可能不太适合1L免疫治疗联合方案（例如，atezolizumab + bevacizumab），包括上/下消化道出血风险（38%）、慢性肾脏疾病（15%）、血栓栓塞事件史（12%）和自身免疫性疾病（5%）。讨论：超过一半的患者有≥1种疾病/合并症，使他们可能不太适合1L免疫治疗组合。这项研究及时地揭示了在现实世界中大量患者中如何使用免疫治疗组合。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.